Nano-encapsulation IP: how delivery-system innovators are filing around lipid nanoparticle and hydrogel matrix claims
The lipid nanoparticle disputes have put a price on delivery IP. Here is what they teach innovators trying to build around existing claims.
For most of the last decade, delivery technology was treated as plumbing: important, but secondary to the drug. The lipid nanoparticle (LNP) disputes changed that. Delivery claims now carry nine- and ten-figure price tags, and every team working in nano-encapsulation needs a strategy for the claims already on file.
What the LNP disputes show
In March 2026, Moderna settled its U.S. and international litigation with Arbutus Biopharma and Genevant Sciences over the LNP technology used in its COVID-19 vaccine, days before a Delaware jury trial. As reported, the terms include $950 million due in July 2026 and up to $1.3 billion more contingent on an appeal concerning 28 U.S.C. § 1498, along with a consent judgment of infringement on the four patents asserted and a non-exclusive licence for infectious-disease uses.
Three of those patents (U.S. Nos. 8,492,359; 9,364,435; and 11,141,378) claim specific molar-ratio ranges for the four lipid components of the particle; a fourth (9,504,651) claims a formulation method. Two points matter for anyone building nearby:
- Ranges are powerful claims. A well-chosen numerical range can cover a large family of formulations without naming a single new molecule.
- Prosecution history narrows them. Before the settlement, the court held that prosecution history estoppel barred the patent owners from relying on the doctrine of equivalents. What an applicant gives up during examination can define where others are free to work.
The fight continues elsewhere. In July 2026, Arbutus announced new actions against Pfizer and BioNTech in the Federal Court of Canada and the Unified Patent Court, expanding its existing U.S. case in New Jersey.
How innovators are filing around
- New components rather than new ratios. Novel ionizable lipids, helper lipids or polymer conjugates create independent claim space instead of competing inside someone else's ranges.
- Process and manufacturing claims. Microfluidic mixing, scale-up and purification methods are protectable even when compositions are crowded.
- Different architectures. Liposomes are classified separately (IPC A61K 9/127, including PEGylated liposomes in A61K 9/1271), and polymeric nanoparticles and hydrogel matrices follow different design rules from LNPs. Moving to a different carrier often moves you into a different claim landscape.
- Hydrogel matrices as depots. Hydrogels that hold and meter out nanoparticles combine two technologies, and claims to the combination and its release profile can stand apart from claims to either part.
- Use and indication claims. Organ-targeted delivery or specific therapeutic uses can be claimed even where the carrier is known.
Our advice
Map the composition ranges in the patents nearest to you before you lock a formulation, read their prosecution histories, and design your data package so that your own claims are supported by real examples rather than predictions. Paxton Scout and our Gelatin & IPR research collection are where we do that groundwork.
This brief is research and analysis, not legal advice.